<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768729</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT CTOTC-01</org_study_id>
    <nct_id>NCT00768729</nct_id>
  </id_info>
  <brief_title>Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation</brief_title>
  <official_title>Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kidney transplantation is widely considered to be the treatment of choice for children with
      End Stage Renal Disease (ESRD). The purpose of this study is to determine the safety of
      sirolimus monotherapy for long-term immunosuppression in children and adolescents after
      kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Improvements in surgical techniques, donor selection, immunosuppression practices, and the
      enhanced experience of specialized pediatric transplant teams have all led to marked
      improvements in patient and kidney graft survival in infants and young children Long-term
      graft survival rates decrease in adolescents 11 to 17 years of age. Several studies have
      suggested this decrease may be the result of noncompliance with immunosuppressive medications
      in this age group. Therefore, protocols that minimize the use of immunosuppressive
      medications, while retaining kidney function are necessary for improving graft and patient
      survival in children. The purpose of this study is to determine the safety of sirolimus
      monotherapy for long-term immunosuppression in children and adolescents after kidney
      transplantation.

      This study will enroll 10 participants who previously completed the CCTPT-PC01 study. The
      accrual period is scheduled for 12 months. The study follow-up period will last 96 weeks.
      Patients from the CCTPT-PC01 study have been maintained on sirolimus and mycophenolate
      mofetil (MMF) since 2-3 months post transplant. Enrolled participants receiving (MMF) or
      Azathioprine at study entry will have their doses withdrawn gradually over a period of 6
      months. Dosage will be reduced by 25% initially and by 25% every 2 months resulting in
      complete withdrawal by 6 months.

      This study will consist of 11 study visits after screening and study entry. Study visits will
      occur at weeks 1, 8, 16, 24, 32, 40, 48, 60, 72, 84, and 96. A physical exam, vital signs,
      sirolimus levels, as well as blood and urine collection will occur at all visits. A renal
      biopsy will be performed at week 96.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per-person incidence of acute rejection episodes and death or graft loss</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic allograft dysfunction</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of sub-clinical rejection</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalizations</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of surgical complications</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resumption of MMF or other therapy</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity, and treatment of anemia, hypertension, hyperlipidemia, proteinuria, thrombocytopenia, and leukopenia</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity, and treatment of opportunistic infections</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven PTLD</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function assessed by measured GFR</measure>
    <time_frame>At baseline, week 48 and week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of donor-specific or non-specific anti-HLA antibodies</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of immune response in cellular, humoral, and molecular assays from baseline through week 96</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.
Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rapamycin, Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF or Azathioprine</intervention_name>
    <description>600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant and/or parent guardian able to understand and willing to provide informed
             consent

          -  Previously enrolled and completed the CCTPT-PC01 study and within the 36 months
             post-completion timeframe prior to study entry

          -  Currently receiving sirolimus and MMF or azathioprine therapy

          -  No history of acute rejection episodes

          -  No evidence of acute or chronic rejection on the 24 month CCTPT-PC01 protocol biopsy
             or any subsequent biopsy obtained after that time prior to study entry

          -  PRA (Class I and II) less than 5% at study entry

          -  No evidence of donor specific antibody at study entry

          -  Stable renal function with GFR greater than 60 cc/min 1.73M^2 using the Schwartz
             calculated method

          -  A negative pregnancy test for female participants of childbearing potential at study
             entry

          -  Agreement by female and male participants to use FDA approved methods of
             contraception.

        Exclusion Criteria:

          -  Total lymphocyte count less than 400 mm^3

          -  Acute or chronic infection at study entry

          -  Treatment with investigational drug within 1 month prior to study entry

          -  Mental illness or history of drug or alcohol abuse that, in the opinion of the
             investigator, would interfere with the study

          -  History of allergic reaction to Iodine GFR assay

          -  History of malignancy within the past 12 months

          -  Inability or unwillingness to give informed consent or comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William H. Harmon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Childrenâ€™s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ctotc.org</url>
    <description>CTOTC Website</description>
  </link>
  <reference>
    <citation>McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W; CCTPT Study Group. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008 May;8(5):984-9. doi: 10.1111/j.1600-6143.2008.02167.x.</citation>
    <PMID>18416737</PMID>
  </reference>
  <reference>
    <citation>Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KG, Thiru S, Jamieson NV, Hale G, Waldmann H, Calne R. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant. 2005 Jun;5(6):1347-53.</citation>
    <PMID>15888040</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage renal disease</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>Kidney failure</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Rapamycin</keyword>
  <keyword>CellCept</keyword>
  <keyword>Mycophenolate mofetil (MMF)</keyword>
  <keyword>Azathioprine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

